XBI156.31 +0.81%IBB218.14 +0.44%S&P 5007,619.38 +1.31%NASDAQ 10028,374.25 +2.28%DOW 3052,486.49 +0.49%FTSE 10010,864.47 +0.27%
Biotech Today Subscribe

Biotechnology Today · FDA & Regulation

Awiqli Wins Pediatric FDA Approval Backed by Adult Studies

Awiqli’s pediatric FDA approval combines controlled adult studies with a single-dose study in children, offering a weekly alternative to daily basal injections.

Yvonne Talbot · 2 min read
Awiqli Wins Pediatric FDA Approval Backed by Adult Studies

Key facts

  • Regulatory decision: FDA approval for once-weekly Awiqli in pediatric type 2 diabetes
  • Eligible population: Children ages 10 and older with type 2 diabetes
  • Basal injection schedule: One injection per week instead of seven
  • Supporting evidence: Controlled adult studies and a single-dose pediatric pharmacokinetic study

The FDA approved Novo Nordisk’s Awiqli as the first and only once-weekly insulin for children ages 10 and older with type 2 diabetes, reducing basal injections from seven per week to one.

The FDA has approved Novo Nordisk’s Awiqli for children ages 10 and older with type 2 diabetes, making it the first and only once-weekly insulin approved for that population. The treatment offers an alternative to daily basal insulin, reducing that injection schedule from seven times a week to one.

The regulatory decision rests on a combination of controlled studies in adults and a single-dose study in pediatric patients. That distinction matters: the evidence supporting the approval is not the same as a long-term trial directly comparing weekly and daily treatment in children.

Adult studies and pediatric drug-exposure evidence

According to Novo Nordisk’s announcement carried by PR Newswire Biotech, the approval was supported by adequate and well-controlled studies in adults with type 2 diabetes and a pediatric pharmacokinetic study. Pharmacokinetics examines how the body handles a medicine, including how drug exposure changes after administration.

Pharmacokinetics examines how the body handles a medicine, including how drug exposure changes after administration.

The pediatric study evaluated those properties after a single dose of Awiqli. It therefore contributes information about drug exposure in children, rather than directly measuring how well children maintain blood-sugar control over an extended treatment period.

The adult studies and pediatric study serve different purposes in the evidence package. The adult research supplies controlled treatment evidence, while the pediatric work helps connect that evidence to the younger population. A single-dose pharmacokinetic study, by its design, cannot establish whether a weekly schedule improves long-term adherence or produces better outcomes than daily injections in children.

A smaller basal-injection burden for families

The practical change is specific to basal insulin—the background insulin component of treatment. For eligible children and their caregivers, a weekly schedule means fewer occasions to administer that component. It does not, by itself, establish that the child’s entire diabetes-care routine becomes weekly.

Eda Cengiz, a professor of pediatrics at the University of California, San Francisco, described sustained blood-sugar control in children with type 2 diabetes as a major challenge. She said a once-weekly basal option could help address administration barriers and give clinicians and families more scope to tailor treatment to individual routines.

That potential benefit should be distinguished from a demonstrated adherence advantage. Fewer scheduled injections may make administration easier for some families, but the frequency change alone does not prove that patients will follow treatment more consistently. The approval expands the available treatment choices; choosing among them remains a clinical decision, including attention to correct dosing, which Novo Nordisk emphasized in its announcement.

Sources

Photo: UlliPixa · Pixabay Content License — source

Filed under Biotechnology Today FDA & Regulation

The Biotech Today briefing

Trials, approvals and the deals moving biotech, in your inbox. Free.

Unsubscribe from any email. See our privacy policy.